Literature DB >> 8642085

Chronic hepatitis C, cryoglobulinemia, and cutaneous necrotizing vasculitis. Clinical, pathologic, and immunopathologic study of twelve patients.

M S Daoud1, R A el-Azhary, L E Gibson, M E Lutz, S Daoud.   

Abstract

BACKGROUND: Several patients with chronic hepatitis C infection and cutaneous vasculitis have been described.
OBJECTIVE: The objective of this study was to define better the features of necrotizing vasculitis and mixed cryoglobulinemia in patients with hepatitis C infection.
METHODS: A retrospective review of 611 patients with hepatitis C antibodies was conducted. Patients with clinical and histopathologic findings of cutaneous necrotizing vasculitis were identified. Clinical, histologic, and laboratory data were recorded.
RESULTS: Twelve patients with necrotizing vasculitis and chronic hepatitis C infection were identified. Palpable purpura was the most common clinical presentation. Onset of skin lesions was usually more than 10 years after infection. The lower extremities were affected in all patients. Cryoglobulinemia of the mixed type II was present in 10 of 11 patients. Liver function tests were evaluated at the time of vasculitis in most of the patients. Rheumatoid factor was elevated in all nine patients tested. Total complement was decreased in seven of nine patients, and C4 was decreased in six of seven patients.
CONCLUSION: Cutaneous vasculitis associated with cryoglobulinemia and hypocomplementemia is not uncommon in the course of chronic active hepatitis C infection. The triad of necrotizing vasculitis, chronic hepatitis C infection, and cryoglobulinemia occurs late after initial infection with hepatitis C. Antibodies to hepatitis C virus should be determined in a patient with necrotizing vasculitis, especially if liver function tests are elevated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642085     DOI: 10.1016/s0190-9622(96)80115-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Transcriptional repression of C4 complement by hepatitis C virus proteins.

Authors:  Arup Banerjee; Budhaditya Mazumdar; Keith Meyer; Adrian M Di Bisceglie; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

2.  Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.

Authors:  Keith Meyer; Arnab Basu; Craig T Przysiecki; L Martin Lagging; Adrian M Di Bisceglie; Anthony J Conley; Ranjit Ray
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response.

Authors:  Malika Ait-Goughoulte; Arup Banerjee; Keith Meyer; Budhaditya Mazumdar; Kousuke Saito; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

4.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

5.  Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients.

Authors:  Soledad Retamozo; Cándido Díaz-Lagares; Xavier Bosch; Albert Bové; Pilar Brito-Zerón; Maria-Eugenia Gómez; Jordi Yagüe; Xavier Forns; Maria C Cid; Manuel Ramos-Casals
Journal:  Medicine (Baltimore)       Date:  2013-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.